{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:32:14Z","timestamp":1788917534704,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014389","name":"Amarin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ajpc.2022.100345","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T22:20:30Z","timestamp":1651098030000},"page":"100345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl"],"prefix":"10.1016","volume":"10","author":[{"given":"Catherine G.","family":"Derington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Bress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Herrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Abrahamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Weintraub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2022.100345_bib0001","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation 2019"},{"key":"10.1016\/j.ajpc.2022.100345_bib0002","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jacl.2018.11.008","article-title":"Hypertriglyceridemia in statin-treated US adults: the National Health and Nutrition Examination Survey","volume":"13","author":"Fan","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0003","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40119-020-00170-x","article-title":"Prevalence of US Adults with Triglycerides \u2265 150 mg\/dl: NHANES 2007\u20132014","volume":"9","author":"Fan","year":"2020","journal-title":"Cardiol and Therapy"},{"key":"10.1016\/j.ajpc.2022.100345_bib0004","article-title":"Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review","volume":"3","author":"Toth","year":"2020","journal-title":"Am J of Preven Cardiol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0005","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2022.100345_bib0006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"New England J of Med"},{"key":"10.1016\/j.ajpc.2022.100345_bib0007","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.119.044440","article-title":"REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2022.100345_bib0009","article-title":"Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT","author":"Weintraub","year":"2021","journal-title":"JAMA Net Open"},{"key":"10.1016\/j.ajpc.2022.100345_bib0010","article-title":"CostEffectiveness of LipidLowering Therapies for Cardiovascular Prevention in Germany","author":"Michaeli","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ajpc.2022.100345_bib0011","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl\u2013Intervention Trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"New England J of Med"},{"key":"10.1016\/j.ajpc.2022.100345_bib0013","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/CIRCULATIONAHA.121.056290","article-title":"Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG","volume":"144","author":"Verma","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2022.100345_bib0014","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jacc.2021.08.009","article-title":"Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT","volume":"78","author":"Gaba","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCULATIONAHA.120.050276","article-title":"Reduction in Revascularization with Icosapent Ethyl: Insights from REDUCE-IT Revascularization Analyses","author":"Peterson","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2022.100345_bib0016","unstructured":"National Center for Health Statistics. NHANES - National Health and Nutrition Examination Survey. n.d. URL: https:\/\/www.cdc.gov\/nchs\/nhanes\/index.htm (Accessed July 21, 2019)."},{"key":"10.1016\/j.ajpc.2022.100345_bib0017","first-page":"1","article-title":"National Health and Nutrition Examination Survey: Plan and Operations, 1999-2010","volume":"1","author":"Zipf","year":"2013","journal-title":"Vital Health Statistics"},{"key":"10.1016\/j.ajpc.2022.100345_bib0018","year":"2013","journal-title":"Specifying Weighting Parameters"},{"key":"10.1016\/j.ajpc.2022.100345_bib0019","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate","volume":"150","author":"Levey","year":"2007","journal-title":"Annal of Intern Med"},{"key":"10.1016\/j.ajpc.2022.100345_bib0020","series-title":"National Health and Nutrition Examination Survey Dietary Supplements and Prescription Medication Questionnaire","year":"2015"},{"key":"10.1016\/j.ajpc.2022.100345_bib0021","series-title":"Consumer Price Index: Medical Care","year":"2020"},{"key":"10.1016\/j.ajpc.2022.100345_bib0022","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis - Principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value in Health"},{"key":"10.1016\/j.ajpc.2022.100345_bib0023","series-title":"Projections of Cardiovascular Disease Prevalence and Costs: 2015-2035","author":"Khavjou","year":"2016"},{"key":"10.1016\/j.ajpc.2022.100345_bib0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/096228029600500306","article-title":"Innovative strategies using SUDAAN for analysis of health surveys with complex samples","volume":"5","author":"LaVange","year":"1996","journal-title":"Stat Method in Med Res"},{"key":"10.1016\/j.ajpc.2022.100345_bib0025","series-title":"The statistical analysis of Failure Time Data","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/j.ajpc.2022.100345_bib0026","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across a range of baseline renal function in patients with established cardiovascular disease or diabetes: results of reduce-it renal","author":"Majithia","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ajpc.2022.100345_bib0027","article-title":"National Population and Cost Implications of Treatment with Icosapentyl Ethyl in the United States: An Assessment Based on the REDUCE-IT trial","author":"Khera","year":"2018","journal-title":"BioRxiv"},{"key":"10.1016\/j.ajpc.2022.100345_bib0028","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2019.01.016","article-title":"Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease","volume":"73","author":"Picard","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0029","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2021.08.031","article-title":"Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registr","volume":"340","author":"Picard","year":"2021","journal-title":"Int J of Cardiol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjcard.2020.08.015","article-title":"REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES])","volume":"134","author":"Wong","year":"2020","journal-title":"Am J of Cardiol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0031","doi-asserted-by":"crossref","first-page":"782","DOI":"10.18553\/jmcp.2020.26.6.782","article-title":"The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease","volume":"26","author":"Synnott","year":"2020","journal-title":"J of Manag Care and Specialty Pharm"},{"key":"10.1016\/j.ajpc.2022.100345_bib0032","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/2047487319896648","article-title":"The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction","volume":"28","author":"Ademi","year":"2021","journal-title":"Eur J of Preven Cardiol"},{"key":"10.1016\/j.ajpc.2022.100345_bib0033","doi-asserted-by":"crossref","first-page":"e415","DOI":"10.1016\/j.amjmed.2020.12.023","article-title":"Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis","volume":"134","author":"Arbel","year":"2021","journal-title":"Am J of Med"},{"key":"10.1016\/j.ajpc.2022.100345_bib0034","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2105\/AJPH.2014.302257","article-title":"The national prevention strategy: Leveraging multiple sectors to improve population health","volume":"105","author":"Lushniak","year":"2015","journal-title":"Am J of Public Health"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667722000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667722000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:38:56Z","timestamp":1763005136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667722000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":34,"alternative-id":["S2666667722000290"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2022.100345","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2022.100345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100345"}}